Analysts Set Insulet Corporation (NASDAQ:PODD) Price Target at $252.48

Insulet Corporation (NASDAQ:PODD) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-seven brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $252.0435.

Several brokerages have recently issued reports on PODD. Canaccord Genuity Group lowered their price objective on shares of Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Evercore lowered their price objective on shares of Insulet from $240.00 to $200.00 in a research note on Thursday, May 7th. Jefferies Financial Group lowered their price objective on shares of Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Citigroup lowered their price objective on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. Finally, Leerink Partners decreased their price target on shares of Insulet from $360.00 to $247.00 in a research note on Thursday, May 7th.

Insulet Trading Up 0.6%

Shares of Insulet stock opened at $143.30 on Thursday. The company’s fifty day simple moving average is $178.57 and its 200-day simple moving average is $240.82. The company has a market cap of $9.92 billion, a price-to-earnings ratio of 33.33, a PEG ratio of 1.12 and a beta of 1.13. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. Insulet has a 1 year low of $140.63 and a 1 year high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. Insulet’s quarterly revenue was up 33.9% on a year-over-year basis. During the same quarter last year, the company posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, sell-side analysts expect that Insulet will post 6.44 EPS for the current year.

Institutional Investors Weigh In On Insulet

Institutional investors have recently bought and sold shares of the business. Nordea Investment Management AB boosted its stake in Insulet by 35.0% during the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock worth $157,128,000 after buying an additional 142,922 shares in the last quarter. Winnow Wealth LLC acquired a new stake in Insulet during the third quarter worth $862,000. ING Groep NV lifted its holdings in shares of Insulet by 88.5% during the third quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock valued at $5,341,000 after acquiring an additional 8,123 shares during the period. Machina Capital S.A.S. bought a new position in shares of Insulet during the third quarter valued at $2,778,000. Finally, Jain Global LLC lifted its holdings in shares of Insulet by 148.2% during the third quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock valued at $32,945,000 after acquiring an additional 63,719 shares during the period.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.